文 献9）Hasegawa H, Kawahata K, Mizoguchi F, Okiyama N, Miyasaka N, Kohsaka H, et al. Direct suppression of autoaggressive CD8+ T cells with CD80/86 blockade in CD8+ T cell-mediated polymyositis models of mice. Clin Exp Rheumatol 2017; 35: 593-7.10）Umezawa N, Kawahata K, Mizoguchi F, Kimura N, Yoshihashi-Nakazato Y, Miyasaka N, et al. Interleukin-23 as a therapeutic target for inflammatory myopathy. Sci Rep 2018; 8: 5498.11）Feng M, Guo H, Zhang C, Wong Y, Liang Z, Zhao X, et al. Absolute reduction of regulatory T cells and regulatory effect of short-term and low-dose IL-2 in polymyositis or dermatomyositis. Int Immuno-pharmacol 2019; 77: 105912.12）Espinosa-Ortega F, Gómez-Martin D, Santana-De Anda K, Romo-Tena J, Villaseñor-Ovies P, Alcocer-Varela J, et al. Quantitative T cell subsets profile in peripheral blood from patients with idiopathic inflammatory myopathies: tilting the balance towards proinflammatory and pro-apoptotic subsets. Clin Exp Immunol 2015; 179: 520-8.13）Sasaki H, Takamura A, Kawahata K, Takashima T, Imai K, Morio T, et al. Peripheral blood lymphocyte subset repertoires are biased and reflect clinical features in patients with dermatomyositis. Scand J Rheumatol 2019; 48: 225-9.14）Maecker HT, McCoy JP, Nussenblatt R. Standardizing immuno-phenotyping for the Human Immunology Project. Nat Rev Immunol 2012; 12: 191-200.15）Kimura N, Hirata S, Miyasaka N, Kawahata K, Kohsaka H. Injury and subsequent regeneration of muscles for activation of local innate immunity to facilitate the development and relapse of autoimmune myositis in C57BL/6 mice. Arthritis Rheumatol 2015; 67: 1107-16.701）Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984; 16: 193-208.2）Karpati G, Pouliot Y, Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol 1988; 23: 64-72.3）Goebels N, Michaelis D, Engelhardt M, Huber S, Bender A, Pongratz D, et al. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest 1996; 97: 2905-10.4）Nishio J, Suzuki M, Miyasaka N, Kohsaka H. Clonal biases of peripheral CD8 T cell repertoire directly reflect local inflammation in polymyositis. J Immunol 2001; 167: 4051-8.5）Barešic M, Bakula M, Anic B. Polymyositis with pulmonary and renal involvement refractory to combined immunosuppressive therapy treated with rituximab. Clin Exp Rheumatol 2016; 34: 720.6）Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 2014; 66: 740-9.7）Takada K, Katada Y, Ito S, Hayashi T, Kishi J, Itoh K, et al. Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/ dermatomyositis: a single-arm clinical trial. Rheumatology (Oxford) 2020; 59: 1084-93.8）Sugihara T, Okiyama N, Suzuki M, Kohyama K, Matsumoto Y, Miyasaka N, et al. Definitive engagement of cytotoxic CD8 T cells in C protein–induced myositis, a murine model of polymyositis. Arthritis Rheum 2010; 62: 3088-92.
元のページ ../index.html#84